Seems like Nextstellis is on the right track as a plant based estrogen.
Cheers......D
************************************************************************ HORMONAL CONTRACEPTIVES MARKET TO SURPASS USD 25.39 BILLION BY 2031 DRIVEN BY RISING AWARENESS AND EXPANDING PRODUCT PORTFOLIO
The hormonal contraceptives market is anticipated to witness significant growth in the coming years, fueled by a surge in awareness regarding family planning methods and the introduction of innovative products by key players.
The Hormonal Contraceptives Market, valued at USD 17.58 Billion in 2023, is projected to reach USD 25.39 Billion by 2031. This translates to a compound annual growth rate (CAGR) of 4.70% throughout the forecast period from 2024 to 2031. Several factors are propelling the industry’s growth, including:
Increasing awareness in emerging economies about hormonal contraception methods.
Growing investments by major players in R&D for novel contraceptive devices.
Supportive initiatives by various governments to increase access to contraceptive products.
Public awareness campaigns by celebrities and healthcare organizations are amplifying knowledge of hormonal contraceptives. The WHO is promoting IUDs, injectables, and implants for high-risk populations. To stay competitive, pharmaceutical companies are investing heavily in research and development. For instance, Mayne Pharma’s FDA-approved NEXTSTELLIS utilizes a plant-based estrogen, potentially offering new advantages to users. These trends point to a flourishing hormonal contraceptives market.
MYX Price at posting:
$4.72 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)